JAK2V617F Homozygosity Arises Commonly and Recurrently in PV and ET, but PV is Characterized by Expansion of a Dominant Homozygous Subclone

Overview

Journal Blood

Publisher Elsevier

Specialty Hematology

Date 2012 Aug 18

PMID 22898600

Citations 46

Authors

Anna L Godfrey

Edwin Chen

Francesca Pagano

Christina A Ortmann

Yvonne Silber

Beatriz Bellosillo

Paola Guglielmelli

Claire N Harrison

John T Reilly

Frank Stegelmann

Fontanet Bijou

Eric Lippert

Mary F McMullin

Jean-Michel Boiron

Konstanze Dohner

Alessandro M Vannucchi

Carlos Besses

Peter J Campbell

Anthony R Green

Affiliations

Soon will be listed here.

Abstract

Subclones homozygous for JAK2V617F are more common in polycythemia vera (PV) than essential thrombocythemia (ET), but their prevalence and significance remain unclear. The JAK2 mutation status of 6495 BFU-E, grown in low erythropoietin conditions, was determined in 77 patients with PV or ET. Homozygous-mutant colonies were common in patients with JAK2V617F-positive PV and were surprisingly prevalent in JAK2V617F-positive ET and JAK2 exon 12-mutated PV. Using microsatellite PCR to map loss-of-heterozygosity breakpoints within individual colonies, we demonstrate that recurrent acquisition of JAK2V617F homozygosity occurs frequently in both PV and ET. PV was distinguished from ET by expansion of a dominant homozygous subclone, the selective advantage of which is likely to reflect additional genetic or epigenetic lesions. Our results suggest a model in which development of a dominant JAK2V617F-homzygous subclone drives erythrocytosis in many PV patients, with alternative mechanisms operating in those with small or undetectable homozygous-mutant clones.

Citing Articles

Shared and distinct genetic etiologies for different types of clonal hematopoiesis.

Brown D, Cato L, Zhao Y, Nandakumar S, Bao E, Gardner E Nat Commun. 2023; 14(1):5536.

PMID: 37684235 PMC: 10491829. DOI: 10.1038/s41467-023-41315-5.

JAK2 V617F allele burden in polycythemia vera: burden of proof.

Moliterno A, Kaizer H, Reeves B Blood. 2023; 141(16):1934-1942.

PMID: 36745865 PMC: 10163319. DOI: 10.1182/blood.2022017697.

Hematopoietic fitness of JAK2V617F myeloproliferative neoplasms is linked to clinical outcome.

Abu-Zeinah G, Di Giandomenico S, Choi D, Cruz T, Erdos K, Taylor E Blood Adv. 2022; 6(18):5477-5481.

PMID: 35789232 PMC: 9631704. DOI: 10.1182/bloodadvances.2022007128.

PD-1/PD-L1, MDSC Pathways, and Checkpoint Inhibitor Therapy in (-) Myeloproliferative Neoplasm: A Review.

Wang J, Sun L Int J Mol Sci. 2022; 23(10).

PMID: 35628647 PMC: 9143160. DOI: 10.3390/ijms23105837.

JAK2 in Myeloproliferative Neoplasms: Still a Protagonist.

Bader M, Meyer S Pharmaceuticals (Basel). 2022; 15(2).

PMID: 35215273 PMC: 8874480. DOI: 10.3390/ph15020160.

References

Moliterno A, Williams D, Rogers O, Isaacs M, Spivak J . Phenotypic variability within the JAK2 V617F-positive MPD: roles of progenitor cell and neutrophil allele burdens. Exp Hematol. 2008; 36(11):1480-6. PMC: 2600434. DOI: 10.1016/j.exphem.2008.05.006. View

Baxter E, Scott L, Campbell P, East C, Fourouclas N, Swanton S . Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005; 365(9464):1054-61. DOI: 10.1016/S0140-6736(05)71142-9. View

James C, Ugo V, Le Couedic J, Staerk J, Delhommeau F, Lacout C . A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005; 434(7037):1144-8. DOI: 10.1038/nature03546. View

Dupont S, Masse A, James C, Teyssandier I, Lecluse Y, Larbret F . The JAK2 617V>F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera. Blood. 2007; 110(3):1013-21. DOI: 10.1182/blood-2006-10-054940. View

Levine R, Belisle C, Wadleigh M, Zahrieh D, Lee S, Chagnon P . X-inactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal.... Blood. 2006; 107(10):4139-41. PMC: 1895292. DOI: 10.1182/blood-2005-09-3900. View

Levine R, Wadleigh M, Cools J, Ebert B, Wernig G, Huntly B . Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005; 7(4):387-97. DOI: 10.1016/j.ccr.2005.03.023. View

Schaub F, Looser R, Li S, Hao-Shen H, Lehmann T, Tichelli A . Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms. Blood. 2010; 115(10):2003-7. DOI: 10.1182/blood-2009-09-245381. View

Zhao R, Follows G, Beer P, Scott L, Huntly B, Green A . Inhibition of the Bcl-xL deamidation pathway in myeloproliferative disorders. N Engl J Med. 2008; 359(26):2778-89. DOI: 10.1056/NEJMoa0804953. View

Scott L, Tong W, Levine R, Scott M, Beer P, Stratton M . JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med. 2007; 356(5):459-68. PMC: 2873834. DOI: 10.1056/NEJMoa065202. View

10.

Vannucchi A, Antonioli E, Guglielmelli P, Rambaldi A, Barosi G, Marchioli R . Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. Blood. 2007; 110(3):840-6. DOI: 10.1182/blood-2006-12-064287. View

11.

Kittur J, Knudson R, Lasho T, Finke C, Gangat N, Wolanskyj A . Clinical correlates of JAK2V617F allele burden in essential thrombocythemia. Cancer. 2007; 109(11):2279-84. DOI: 10.1002/cncr.22663. View

12.

Passamonti F, Rumi E, Pietra D, Elena C, Boveri E, Arcaini L . A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. Leukemia. 2010; 24(9):1574-9. DOI: 10.1038/leu.2010.148. View

13.

Delhommeau F, Dupont S, Valle V, James C, Trannoy S, Masse A . Mutation in TET2 in myeloid cancers. N Engl J Med. 2009; 360(22):2289-301. DOI: 10.1056/NEJMoa0810069. View

14.

Schaub F, Jager R, Looser R, Hao-Shen H, Hermouet S, Girodon F . Clonal analysis of deletions on chromosome 20q and JAK2-V617F in MPD suggests that del20q acts independently and is not one of the predisposing mutations for JAK2-V617F. Blood. 2008; 113(9):2022-7. DOI: 10.1182/blood-2008-07-167056. View

15.

Kralovics R, Passamonti F, Buser A, Teo S, Tiedt R, Passweg J . A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005; 352(17):1779-90. DOI: 10.1056/NEJMoa051113. View

16.

Chen E, Beer P, Godfrey A, Ortmann C, Li J, Costa-Pereira A . Distinct clinical phenotypes associated with JAK2V617F reflect differential STAT1 signaling. Cancer Cell. 2010; 18(5):524-35. PMC: 2996868. DOI: 10.1016/j.ccr.2010.10.013. View

17.

Lacout C, Pisani D, Tulliez M, Gachelin F, Vainchenker W, Villeval J . JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood. 2006; 108(5):1652-60. DOI: 10.1182/blood-2006-02-002030. View

18.

Li S, Kralovics R, De Libero G, Theocharides A, Gisslinger H, Skoda R . Clonal heterogeneity in polycythemia vera patients with JAK2 exon12 and JAK2-V617F mutations. Blood. 2008; 111(7):3863-6. DOI: 10.1182/blood-2007-09-111971. View

19.

Tiedt R, Hao-Shen H, Sobas M, Looser R, Dirnhofer S, Schwaller J . Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice. Blood. 2007; 111(8):3931-40. DOI: 10.1182/blood-2007-08-107748. View

20.

Plo I, Nakatake M, Malivert L, de Villartay J, Giraudier S, Villeval J . JAK2 stimulates homologous recombination and genetic instability: potential implication in the heterogeneity of myeloproliferative disorders. Blood. 2008; 112(4):1402-12. DOI: 10.1182/blood-2008-01-134114. View